Jacob Graham, MBS
Mr. Graham works with clients to identify and demonstrate the value of life science innovation to influence product adoption across key stakeholders.
With experience, insight, and extensive knowledge of market and economic forces, Quorum Consulting delivers answers that work for our clients—repeatedly.
Developing comprehensive market access, evidence, and pricing strategies that are actionable and leverage insights from payers, physicians, and other stakeholders.
Mr. Graham works with clients to identify and demonstrate the value of life science innovation to influence product adoption across key stakeholders.
Mr. Scott develops actionable strategies that address payer requirements and drive provider adoption, ultimately enabling widespread access for novel technologies.
Ms. Littmann brings over 15 years of implementing customer and field programs to novel programs for niche markets and disruptive technologies.
Developing the evidence necessary to optimize product adoption, coverage, and reimbursement – from developing the premise and analysis plan to carrying out the requisite research or building models for various payer or customer audiences, including exploring nontraditional and mixed-methods pathways.
Dr. Arnold is a pioneer in the development and use of HEOR methods in comparative effectiveness research. In particular, Dr. Arnold has developed and promoted use of real-world evidence to support coverage and payment decisions in and outside of the US.
Mr. Layton specializes in analyzing data and applying analytics to reimbursement policy initiatives. He has extensive experience working with providers on data collection, profitability analyses, and operational efficiency analysis.
This cost-of-care analysis assesses open-angle glaucoma costs over 5 years after initial treatment with two trabecular micro-bypass stents (iStents), selective laser trabeculoplasty (SLT), or medications only.
In a study using 5% Medicare Standard Analytical Files, post-creation procedures and associated costs for surgically created hemodialysis arteriovenous fistulas (AVF) were found to be statistically significantly greater than those for a new endovascularly created AVF.
Applying innovation to the design of reimbursement hotlines, appeal case management programs, and responsive customer and field team arrangements, as well as creating reliable, consistent feedback loops to support your broader market access strategies.
Ms. Littmann brings over 15 years of implementing customer and field programs to novel programs for niche markets and disruptive technologies.